Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

As the company gains more information about the patient death, dosing in the other phase 3 trial, CIFFREO, has been paused until further notice. 

Patient Death Reported in Phase 2 DAYLIGHT Study of Pfizer’s Gene Therapy for Duchenne

Videos

The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]

Promising Nasal Administration Treatment for Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS

The associate director, Patient Reported Outcomes, Johnson & Johnson, provided clarity on a poster presentation from AAN 2024 examining the most critical aspects to CIDP disease severity.

NeuroVoices: Kayla Scippa, on Recognizing Unmet Need in Chronic Demyelinating Polyneuropathy

STS101 demonstrated mild and predictable adverse events, suggesting potential efficacy at 5.2 mg dose for migraines.

Crossover Study Highlights Pharmacokinetic Effects of DHE Powder STS101

Chief of the Division of MS and Neuroimmunology at UConn Health.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]

A Call to Action to Address Disparities in Multiple Sclerosis Care: Jaime Imitola, MD

, has been with the team since October 2019. Follow him on Twitter 

The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]

Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD

The chief scientific officer of the Parkinson’s Foundation and chief executive officer of Tasso discussed their company partnership to expand and accelerate genetic research in Parkinson Disease. [WATCH TIME: 6 minutes]

Using a Blood Collection Device to Advance Genetic Research in Parkinson Disease: James Beck, PhD & Ben Casavant, PhD

Director, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic 

The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]

Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Cure SMA:  Evaluation of SMA in the Era of Telehealth

Cure SMA

SAP Partners

The NeurologyLive Cure Connections series, “Evaluation of Spinal Muscular Atrophy in the Era of Telehealth,” put on in partnership with Cure SMA, features Diana Castro, MD, and Garey H. Noritz, MD, who offer tips and demonstrations for screening and diagnosing SMA via telehealth. Additionally, resources provided by Cure SMA are outlined for families and clinicians who suspect SMA or have a patient diagnosed with SMA.

Diana Castro, MD walks us through a pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Pediatric Neurological Exam to Identify SMA

Garey H. Noritz, MD, walks us through a virtual pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy 

Early recognition and referral of a patient with suspected spinal muscular atrophy (SMA) to a neurologist.

Referral of SMA to a Neurologist

Diana Castro, M.D., discusses newborn screening for spinal muscular atrophy (SMA) and suggests how to care for patients after the results are received.  

Newborn Screening for SMA

The signs and symptoms leading a pediatrician to a diagnosis of spinal muscular atrophy (SMA) are discussed.

Signs and Symptoms of SMA

Diana Castro, M.D., stresses the value of the initial in-person neurology visit for evaluation of spinal muscular atrophy (SMA) to ensure a correct diagnosis. The next step in the process would be genetic testing.

Evaluation of Suspected SMA via In-Person and Remote Exam

Discussing the diagnosis of spinal muscular atrophy (SMA) with the family and lining up appointments with the multidisciplinary team to help care for the patient.

Discussing the Diagnosis of SMA With the Family

Several spinal muscular atrophy (SMA) resources are suggested to help physicians and families, including Cure SMA and standard of care guidelines.

SMA Resources for Physicians and Families

Resources are discussed, including the Child Neurology Foundation’s telehealth tip sheet, to help families navigate telehealth.

Telehealth During COVID-19

Experts remind families of the importance of follow-up visits with the multidisciplinary team during COVID-19.

Importance of Follow-Up Visits for SMA Amid COVID-19

Closing thoughts on advice to community neurologists treating spinal muscular atrophy (SMA).

Advice to Community Neurologists Treating SMA

SAP Partner

Clinical

 video series brings together expert clinicians and patients with neurologic diseases and disorders to discuss the landscapes of care, management, and treatment from both perspectives.

Pediatric Neurological Exam to Identify SMA

EP: 1.Pediatric Neurological Exam to Identify SMA

EP: 2.Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

EP: 3.Referral of SMA to a Neurologist

EP: 4.Newborn Screening for SMA

EP: 5.Signs and Symptoms of SMA

EP: 6.Evaluation of Suspected SMA via In-Person and Remote Exam

EP: 7.Discussing the Diagnosis of SMA With the Family

EP: 8.SMA Resources for Physicians and Families

EP: 9.Telehealth During COVID-19

EP: 10.Importance of Follow-Up Visits for SMA Amid COVID-19

EP: 11.Advice to Community Neurologists Treating SMA